Tor 20 jun / År 42 / Nr 3 2024

Life Science 2021

The task of developing the healthcare systems, technology and treatments of the future requires a much sharper focus on facilitating collaboration across borders. Not only geographical – but across disciplines as well. Gothenburg has a strong and growing Life Science cluster which deserves to be highlighted from a national point of view.

Improved analytic performance in fluidic systems by elimination of dissolved gasses by proper degassing

Modern science is highly dependent on analytical equipment. A wide range of analytical technologies provides data for decision making. However, no system is stronger than the weakest link. In more or less any fluidic system dissolved gasses may cause disruption seen as noise in the read out reducing the overall performance. The Swedish company Biotech AB provides solutions to this.

Degasing in action.

Modern chemical analysis is based on highly advanced instruments with extremely high sensitivity. Chemical analyses within drug development, clinical diagnostics, environmental research and in forensic investigations are just a few examples.

In any fluidic system gasses dissolved in the fluid threaten to cause noise in the output signal by forming microbubbles. The formation of microbubbles occurs when the gas solubility in the fluid decreases. This typically happens as a result of local pressure drops or heating and during mixing of different fluids. Even though these bubbles may disappear just as quickly as they were formed an inconsistency in the system is formed. This is often observed as baseline noise.

“The formation of bubbles can completely destroy the accuracy of any fluidic analysis and can be seen as disturbing baseline noise. We have developed degassing systems that efficiently improve the accuracy, precision and performance of such systems”, explains Anders Grahn, Chairman of the Board of Directors and Founder of Biotech.

Biotech AB was founded by Anders Grahn and Ralf Jutvik some 15 years ago. Since then Biotech AB has provided degassing and fluidic solutions to a steadily growing number of instrument manufacturers all over the world. At the age of 95, Ralf Jutvik decided to retire but he is still highly involved in the company and remains co-owner and board member. By the end of 2020 Fritiof Pontén took over as CEO. His background from AstraZeneca and the start-up biopharma sector gives him good understanding and insight of customer needs and requirements.

Where are degassers used?

The degasser is not only an essential component of most liquid chromatography systems such as HPLC, UHPLC, ion chromatography and LCMS but also within surface plasmon resonance (SPR) and other emerging analytical technologies. Developers and manufacturers of instrumentation within immunology, hematology and in vitro diagnostics has also found that proper degassing makes their instrument better by delivering more consistent results. Even suppliers within the semi-conductor manufacturing industry has found that degassing improves their end product. The customer base includes start-ups as well as the global market leaders in the field.

“Our customers are based all over the world. Any company working with sophisticated fluidic equipment of any kind is a potential client. In turn, their customers and the end users, typically pharmaceutical drug developers, hospital laboratories, CROs and biotech companies, will have access to a better instrument” says CEO Fritiof Pontén. 

Joining forces is the future

As a company, Biotech is currently growing with well-established subsidiaries in the USA and Japan. Fritiof Pontén keeps a close eye on the development at the AstraZeneca Bioventure Hub and now the launch of GoCo Health Innovation City.

“We look forward to the continued development of new collaboration platforms in the Gothenburg region at large, as we have our roots here and our head office remains here. Even more importantly, Biotech AB strives to work together with developers within the Swedish Life Science cluster to bring new products to the global market. Biotech AB has a well-established global network of high keen OEM customers with scientific instrumentation and sees excellent opportunities to bring new products to this market by joint forces”, Pontén concludes.